Tetrahydrobiopterin treatment in phenylketonuria: A repurposing approach

Area of Science:

• Biochemistry
• Neuroscience
• Genetics

Background:

• Phenylketonuria (PKU) is a genetic disorder requiring early diagnosis and dietary management to prevent intellectual disability.
• Despite treatment, some PKU patients experience suboptimal neurocognitive outcomes, necessitating additional therapeutic strategies.
• Tetrahydrobiopterin (BH4) is a cofactor for phenylalanine hydroxylase and may offer therapeutic benefits in PKU.

Purpose of the Study:

• To review the theoretical mechanisms by which BH4 may directly improve neurocognitive functioning in PKU patients.
• To explore BH4's potential to cross the blood-brain barrier and influence brain function.
• To identify potential BH4 treatment regimens for enhancing neuropsychological outcomes in PKU.

Main Methods:

• Literature review of existing studies on BH4 metabolism and its effects in PKU.
• Analysis of theoretical pathways for BH4's direct impact on neurocognitive function.
• Examination of BH4's role in both BH4-responsive and BH4-unresponsive PKU patient populations.

Main Results:

• BH4 may enhance residual phenylalanine hydroxylase activity in responsive PKU patients.
• BH4 might directly improve neurocognitive function by influencing neurotransmitter synthesis or other brain mechanisms.
• These potential direct effects are hypothesized to occur in both BH4-responsive and BH4-unresponsive PKU patients.

Conclusions:

• BH4 presents a potential therapeutic strategy to improve neurocognitive outcomes in PKU, independent of its effect on phenylalanine metabolism.
• Further research is needed to elucidate the precise mechanisms of BH4's direct neurocognitive effects and optimize treatment regimens.
• Repurposing BH4 could significantly improve mental health and neuropsychological outcomes for a broader PKU patient population.